The Effects of Cognitive Behavioral Therapy for Insomnia on Cardiovascular and Immunological Outcomes: A Randomized-Controlled Study

Technical Summary: The Effects of Cognitive Behavioral Therapy for Insomnia on Cardiovascular and Immunological Outcomes

Problem Statement
Insomnia disorder is characterized by nocturnal and diurnal sleep complaints and is associated with physiological dysregulation across cardiac, hormonal, and immune systems. This state of hyperarousal is considered a core feature of the disorder, potentially contributing to long-term physical and inflammatory health risks. While Cognitive Behavioral Therapy for Insomnia (CBTi) is the established first-line treatment for reducing insomnia severity, its capacity to reverse underlying pathophysiological alterations—specifically regarding cardiovascular and immunological biomarkers—remains unclear. Previous literature presents inconsistent findings, with some studies suggesting reductions in blood pressure (BP) or inflammatory markers and others reporting null effects. Furthermore, prior research often utilized active control conditions (e.g., sleep education) that may attenuate between-group differences, or focused on single physiological systems. This study addresses these gaps by examining whether CBTi produces clinically meaningful changes in cardiovascular and inflammatory biomarkers compared to a waitlist control in a randomized-controlled trial (RCT) design.

Methodology
This study utilized secondary analyses from a registered RCT (ISRCTN13983243) involving 62 adults diagnosed with chronic insomnia disorder (DSM-5 criteria). Participants were randomized into two groups:

• Treatment Group (TX, N=33): Received an 8-session group CBTi program over 3 months, delivered by licensed psychologists. The intervention included cognitive restructuring, behavioral strategies (sleep restriction, stimulus control), relaxation training, and sleep hygiene education.
• Waitlist Control Group (WL, N=29): Underwent a 3-month monitoring period before receiving the same CBTi program.

Assessments:
Data were collected at three time points:

• T1 (Baseline): Prior to randomization.
• T2 (Post-treatment): 3 months post-randomization (after CBTi for TX; after WL period for WL).
• T3 (Follow-up): 6 months post-randomization (after CBTi for WL participants).

Measured Outcomes:

1. Cardiovascular Parameters:
   • Resting Systolic (SBP) and Diastolic Blood Pressure (DBP) and Heart Rate (HR) measured via continuous noninvasive arterial pressure monitoring and ECG during a 5-minute morning resting state.
   • Nocturnal Heart Rate Variability (HRV) derived from continuous ECG recordings during sleep. Analyses covered the entire night and the first 90 minutes of sleep. Metrics included time-domain measures (SDNN, RMSSD) and frequency-domain measures (Low Frequency [LF], High Frequency [HF]).
2. Immunological Markers:
   • Blood samples collected after an overnight fast were analyzed for C-reactive protein (CRP), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and Brain-Derived Neurotrophic Factor (BDNF) using multiplex V-Plex kits.

Statistical Analysis:
Linear mixed-effects models were employed to examine Group (TX vs. WL) × Time (Pre vs. Post) interactions, controlling for age and sex. An intention-to-treat approach was used. To increase statistical power, a secondary analysis pooled data from participants who received CBTi (TX group T1–T2 and WL group T1–T3) to assess changes over time following treatment exposure. The Benjamini-Hochberg False Discovery Rate (FDR) procedure was applied to correct for multiple testing within families of outcomes.

Key Results

• Cardiovascular Outcomes: No significant Group × Time interactions were observed for SBP, DBP, HR, or any HRV indices (SDNN, RMSSD, LF, HF) from T1 to T2. Similarly, when pooling data across both groups to assess changes following CBTi exposure, no significant main effects of time were found for any cardiovascular biomarker.
• Immunological Outcomes: No significant Group × Time interactions were observed for CRP, TNF-α, IL-6, or BDNF. When pooling data to assess treatment effects, no significant changes in inflammatory markers were detected pre- to post-CBTi.
• Demographics and Covariates: The sample was predominantly female (75.8%), White (74.2%), and university-educated. While age was significantly associated with higher SBP and DBP, and sex showed some uncorrected associations with HR and HRV, these covariates did not alter the primary finding of null treatment effects.
• Subjective vs. Physiological: The authors note that the parent study on this same dataset previously reported significant improvements in subjective insomnia severity following CBTi, yet these subjective improvements were not accompanied by detectable changes in objective sleep measures or the physiological biomarkers assessed here.

Significance and Claims
The study concludes that in a sample of healthy individuals with chronic insomnia, CBTi does not produce detectable changes in cardiovascular or inflammatory biomarkers within a 3-to-6-month timeframe. The authors suggest several interpretations for these null findings:

1. Sample Characteristics: The participants were generally healthy with normal baseline blood pressure readings, potentially creating floor effects that limited the ability to detect improvements. The authors posit that CBTi might yield physiological benefits in higher-risk or comorbid populations (e.g., those with cardiovascular disease).
2. Temporal Dynamics: The follow-up interval may have been insufficient to capture long-term physiological adaptations, as some literature suggests inflammatory changes may require longer durations (e.g., 16 months) to manifest.
3. Complexity of Mechanisms: The findings suggest a dissociation between subjective sleep improvements and systemic physiological changes. The authors propose that physiological responses to CBTi may be complex, context-dependent, or related to specific sleep stages rather than global systemic markers.

The paper emphasizes that while CBTi is effective for symptom reduction, its role as a tertiary prevention strategy for reducing cardiovascular and inflammatory disease risk via these specific biomarkers remains unproven in healthy insomnia populations. Future research is called for with larger, more diverse, and higher-risk samples to better elucidate the biological mechanisms underlying insomnia treatment.